Latest Filings

Issuer Activity

Insider Overview :: Acasti Pharma Inc. (V:APO) [?]
Business Focus: Pharmaceuticals Share on StockTwits
Recent Price for APO
CAD 1.09 -0.04 (-3.54%)
TSXV Delayed 15 minutes
Apr 24 1422 EDT
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
1.13 4.32 N/A 22,500 115.39
1-Day Low 52-Week Low Yield Avg. Volume  
1.09 1.04 0.0% 24,328  
Log in or sign up for a free account to add this stock to your watch list.

Holdings trends & enhanced charts available in PDF report. Click here for details »
Latest 10 SEDI filings (by transaction date) for APO within the last 6 months [?]
Amended Filing
As of 11:59pm ET April 23rd, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Feb 13/14 Feb 10/14 Lauzon, Claudie Direct Ownership Common Shares (Actions de catégorie A) 10 - Disposition in the public market -3,750 $1.43
Feb 5/14 Feb 4/14 Lemieux, Pierre Direct Ownership Common Shares (Actions de catégorie A) 10 - Disposition in the public market -12,500 $1.34
Feb 3/14 Jan 30/14 Harland, Xavier Direct Ownership Common Shares (Actions de catégorie A) 10 - Disposition in the public market -15,000 $1.40
Feb 25/14 Jan 24/14 Waksal, Harlan Direct Ownership Common Shares (Actions de catégorie A) 57 - Exercise of rights 40,833 $1.43
Feb 25/14 Jan 24/14 Waksal, Harlan Direct Ownership Restricted Share Units 57 - Exercise of rights -40,833 $1.43
Feb 25/14 Jan 24/14 Sampalis, Fotini Direct Ownership Common Shares (Actions de catégorie A) 57 - Exercise of rights 2,500 $1.43
Feb 25/14 Jan 24/14 Sampalis, Fotini Direct Ownership Restricted Share Units 57 - Exercise of rights -2,500 $1.43
Feb 25/14 Jan 24/14 Ripplinger, John Direct Ownership Common Shares (Actions de catégorie A) 57 - Exercise of rights 2,500 $1.43
Feb 25/14 Jan 24/14 Ripplinger, John Direct Ownership Restricted Share Units 57 - Exercise of rights -2,500 $1.43
Feb 25/14 Jan 24/14 Massrieh, Wael Direct Ownership Common Shares (Actions de catégorie A) 57 - Exercise of rights 6,250 $1.43
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Latest 10 SEDI filings (by filing date) for APO within the last 6 months [?]
Amended Filing
As of 11:59pm ET April 23rd, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Feb 26/14 Sep 10/13 Timperio, Michel Direct Ownership Common Shares (Actions de catégorie A) 10 - Disposition in the public market -50,000 $2.71
USD
Feb 25/14 Jan 24/14 Waksal, Harlan Direct Ownership Common Shares (Actions de catégorie A) 57 - Exercise of rights 40,833 $1.43
Feb 25/14 Jan 24/14 Waksal, Harlan Direct Ownership Restricted Share Units 57 - Exercise of rights -40,833 $1.43
Feb 25/14 Jan 24/14 Sampalis, Fotini Direct Ownership Common Shares (Actions de catégorie A) 57 - Exercise of rights 2,500 $1.43
Feb 25/14 Jan 24/14 Sampalis, Fotini Direct Ownership Restricted Share Units 57 - Exercise of rights -2,500 $1.43
Feb 25/14 Jan 24/14 Ripplinger, John Direct Ownership Common Shares (Actions de catégorie A) 57 - Exercise of rights 2,500 $1.43
Feb 25/14 Jan 24/14 Ripplinger, John Direct Ownership Restricted Share Units 57 - Exercise of rights -2,500 $1.43
Feb 25/14 Jan 24/14 Massrieh, Wael Direct Ownership Common Shares (Actions de catégorie A) 57 - Exercise of rights 6,250 $1.43
Feb 25/14 Jan 24/14 Massrieh, Wael Direct Ownership Restricted Share Units 57 - Exercise of rights -6,250 $1.43
Feb 25/14 Jan 24/14 Lemieux, Pierre Direct Ownership Restricted Share Units 57 - Exercise of rights -12,500 $1.43
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Sign up for an account or login above to see the past 6 months of SEDI filings sorted by insider.
No Markers (TSX Insider Summaries) for APO on April 23, 2014 [?]
To view marker data for the past week, sign up for an account or log in above.
To view more history, sign up for an account at inkresearch.com
Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEDAR
Key People
Ronald Denis
Independent Chairman of the Board
Henri Harland
President, Chief Executive Officer, Secretary, Director
Xavier Harland
Chief Financial Officer
Pierre Lemieux
Chief Operating Officer
Harlan W. Waksal
Executive Vice President - Business and Scientific Affairs
Tina Sampalis
Chief Global Strategy Officer
Company Contact
Address: Suite 100, 545 Promenade du Centropolis
LAVAL QC H7T 0A3
Tel: N/A
Website: www.acastipharma.com
IR: See website
Business Overview
Acasti Pharma Inc. (Acasti) is engaged in developing a product portfolio of long-chain omega-3 phospholipids. Acasti is a majority owned subsidiary of Neptune Technologies and Bioressources Inc. (Neptune). The Company has one operating segment: the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The Company's product portfolio includes concentrated phospholipids which functionalize eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Acasti is the producer of anti-dyslipidemic prescription drugs (CaPre), medical foods (Onemia) and over-the-counter (OTC) products (Vectos). During the fiscal year ended February 28, 2011 (fiscal 2011), the Company has completed the development and launched medical food, Onemia.
Financial Overview
For the nine months ended 30 November 2013, Acasti Pharma Inc revenues decreased 55% to C$301K. Net loss increased 83% to C$9.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Finance Costs increase from C$2K to C$552K (expense), General and administrative expenses increase of 16% to C$1.2M (expense).
Reporting Currency: Canadian Dollars
Enterprise value: $114.84M as of Nov 30, 2013
Annual revenue (TTM): $0.35M as of Nov 30, 2013
EBITDA (TTM): -$9.20M as of Nov 30, 2013
Net annual income (TTM): -$11.01M as of Nov 30, 2013
Free cash flow (TTM): -$2.20M as of Nov 30, 2013
Net Debt Last Fiscal Year: N/A
Shares outstanding: 105,862,179 as of Feb 18, 2014
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization
Competitors with Recent Insider Filings
Cipher Pharmaceuticals (T:DND)
Valeant Pharmaceuticals (T:VRX)
BioSyent (V:RX)
 
Acasti Pharma Inc. Insider Report Only $20.00